Shukra Pharmaceuticals Ltd has secured a letter of intent for 10 acres at YEIDA’s Medical Device Park in Greater Noida, committing ~₹600 crore to manufacture surgical robotics and Boron Neutron Capture Therapy systems. The project, alongside a partnership with Borns Medical Robotics, aims to expand affordable robotic surgery and advanced cancer treatment across India and Asia.
Shukra Pharmaceuticals Ltd has taken a major step into advanced medical technology manufacturing after receiving a letter of intent from the Yamuna Expressway Industrial Development Authority (YEIDA) for 10 acres of land at the Medical Device Park in Sector 28, Greater Noida. The company plans to invest approximately ₹600 crore in the facility, which will focus on surgical robotics and Boron Neutron Capture Therapy (BNCT)—a next-generation treatment for complex cancer cases.
The proposed facility is expected to generate more than 900 direct jobs and around 2,000 indirect employment opportunities, reinforcing India’s ambition to become a global hub for high-end medical devices and healthcare innovation.
Moving beyond pharmaceuticals into medtech manufacturing
The YEIDA-backed project marks a strategic expansion for Shukra Pharmaceuticals beyond conventional pharmaceuticals into high-value medical technology manufacturing. By locating the facility within a designated medical device park, the company gains access to specialised infrastructure, regulatory support, and proximity to an emerging ecosystem of device manufacturers and research institutions.
The plant will manufacture advanced robotic surgical systems alongside BNCT technology, which is increasingly being explored globally for its ability to selectively target cancer cells while minimising damage to surrounding healthy tissue.
Partnership brings AI-driven surgical robotics to India
Alongside the land allocation, Shukra Pharmaceuticals signed a Memorandum of Understanding (MoU) with Borns Medical Robotics Inc. to introduce the Veer Surgical Robot in India. The MoU was formalised at an event in New Delhi and represents one of the more ambitious attempts to localise advanced robotic surgery platforms in the country.
The Veer Surgical Robot is an AI-driven surgical system designed to improve precision, standardise outcomes, and enhance patient safety. Importantly, the platform is positioned as a more affordable alternative to existing robotic surgery systems, which have historically been limited to large metro hospitals due to high acquisition and operating costs.
Dr. Minakshi Late, CEO and Global Head of Shukra Ltd., underscored the national importance of the initiative, saying:
“Our joint venture with Borns is a contribution towards making India Atmanirbhar Bharat, and our efforts will be to make it affordable and accessible to patients who deserve this technology the most. Our efforts will be to make this technology affordable and accessible to patients who deserve it the most, particularly in underserved regions.”
Aiming to democratise robotic surgery
Global robotic surgery adoption has grown rapidly over the past decade, but in India, access remains uneven. High capital costs, dependence on imported systems, and limited training infrastructure have constrained adoption largely to premium hospitals.
Shukra and Borns are positioning their partnership as a response to these challenges. Dr. Alexander T. Teichmann, Chief Medical Officer at Borns Medical Robotics Inc., said:
“This joint venture fuses Borns’ cutting-edge AI-driven robotics with Shukra’s vision and market reach. Together, we’re empowering surgeons, standardizing outcomes, and building scalable healthcare infrastructure across India and Asia: ushering in a new era of affordable, accessible, and high-precision surgery.”
Dakshesh Shah, Chairman and Managing Director of Shukra Pharmaceuticals, emphasised affordability and geographic reach:
“Every Indian deserves access to the best healthcare technology. Our vision is to make world-class technology available in India at affordable prices. Through this partnership with Borns Medical Robotics, we’re taking a significant step toward democratizing advanced surgical care and ensuring that cutting-edge robotic surgery is no longer confined to just metro cities or premium healthcare facilities.”
Clinical validation and regulatory progress
The Veer Surgical Robot has already undergone its first-ever human clinical trial, evaluating safety and efficacy across a range of basic to advanced surgical procedures. According to the companies, the results demonstrated strong performance in terms of precision, safety, and clinical outcomes.
The findings have been published in international medical journals and reported to India’s drug and device regulator, the CDSCO. Commercial deployment of the system is expected to begin in Q2 2026, initially across leading hospitals, followed by a broader rollout.
Dr. Vivek Bindal, Director and Head of Max Institute of Robotic Surgery, Patparganj, who participated in early trials, said:
“Robotic surgery has revolutionized surgical care, but access has remained limited due to high costs and restricted availability. The introduction of next-generation platforms like Veer marks a transformative shift… This means high-quality, minimally invasive procedures become more accessible and affordable for a broader patient population across India; empowering surgeons and improving outcomes for those who need it most.”
Building a full ecosystem, not just a factory
Beyond manufacturing, the Shukra–Borns partnership aims to build a broader ecosystem around robotic surgery in India. This includes surgeon training programs, infrastructure development, and support for hospitals in tier-2 and tier-3 cities, where access to advanced surgical technology has traditionally lagged.
If executed as planned, the YEIDA facility could become a cornerstone of India’s medical device manufacturing ambitions—supporting not just domestic demand but potentially exports across Asia, while aligning with national priorities around self-reliance, skilled employment, and affordable healthcare innovation.
